Business Context and Reporting Period
Company: iSpecimen Inc. (ISPC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: iSpecimen operates a proprietary online marketplace connecting medical researchers with hospitals and laboratories to procure biospecimens (human biofluids, tissues, and cells). The company acts as a principal in these transactions, managing the procurement process and bearing credit risk.
Corporate Actions: The company executed a 1-for-20 reverse stock split effective September 13, 2024, to regain compliance with Nasdaq listing rules. All share and per-share data in this report reflect this split retroactively.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Balance Sheet (Sept 30, 2024) |
|---|---|---|---|
| Revenue | $2,661,936 | $7,815,608 | — |
| Net Loss | $(1,439,853) | $(6,450,994) | — |
| Loss Per Share (Basic & Diluted) | $(2.10) | $(11.30) | — |
| Cash and Cash Equivalents | — | — | $1,751,854 |
| Working Capital | — | — | $(1,610,379) |
| Total Assets | — | — | $11,264,223 |
| Total Liabilities | — | — | $6,549,651 |
| Stockholders' Equity | — | — | $4,714,572 |
Operating Cash Flow (Nine Months): Net cash used in operating activities was $(4,691,032), an improvement of 24% compared to the prior year period.
Material Changes vs. Prior Period
- Revenue: For the nine months ended September 30, 2024, revenue increased 6% ($462,518) compared to the prior year, driven by a 5% increase in specimen count. However, for the three-month period, revenue decreased 4% due to a 39% drop in average selling price per specimen, partially offset by a 58% increase in volume.
- Operating Expenses: Total operating expenses decreased 6% year-over-year for the nine-month period. Significant reductions were seen in Supply Development (-48%) and Sales & Marketing (-20%) due to workforce reductions and cost-cutting measures.
- Technology Capitalization: Capitalization of internally developed software dropped 83% year-over-year for the nine-month period (from $3.5M to $0.6M) as the company shifted focus from development to revenue generation.
- Other Income: Other income increased significantly (61% for nine months) primarily due to a non-cash reversal of a previously accrued sales tax liability.
- Liquidity: Working capital turned negative, moving from a positive $2.2M at year-end 2023 to a deficit of $(1.6M) at September 30, 2024. Available-for-sale securities matured and were not replaced, reducing total liquid assets.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
Management has raised substantial doubt regarding the company's ability to continue as a going concern for one year from the filing date. This is due to recurring losses, an accumulated deficit of $65.8M, and negative working capital. The company's viability depends on raising additional capital and achieving profitable operations.
Capital Raising Activities
- Debt Financing: In September 2024, the company secured a $1.0M senior note payable at 18% interest. This note was paid off in full (principal plus $18k interest) on October 31, 2024.
- Equity Offering: In October 2024 (subsequent to period end), the company closed a public offering raising approximately $5.0M in gross proceeds via common stock and pre-funded warrants.
- ATM Offering: During the nine months ended September 30, 2024, the company raised approximately $1.5M gross proceeds under its At-the-Market (ATM) agreement.
Risks and Contingencies
- Sales Tax Liability: The company identified a material weakness in internal controls regarding sales tax collection. As of September 30, 2024, the accrued liability for sales tax, interest, and penalties was reduced to approximately $551,000 ($407k tax + $144k penalties) from a prior estimate of ~$922k, following customer exemption verifications and jurisdictional confirmations.
- Legal Proceedings: A former Chief Information Officer filed a demand for arbitration claiming $586,800 in unpaid bonuses and severance. The company intends to vigorously defend against these claims.
- Geopolitical Risk: Ongoing conflict in Ukraine and Russia continues to impact supply chain logistics and economics, though the company has diversified sourcing to mitigate reliance on these regions.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.75M cash balance combined with the $5.0M raised in the October 2024 offering to cover the negative operating cash flow of ~$4.7M per nine months.
- Sales Tax Resolution: Monitor the status of the sales tax liability remediation and any remaining exposure from jurisdictions where exemption letters were not obtained.
- Revenue Quality: Assess the sustainability of revenue growth given the significant decrease in average selling price per specimen in Q3 2024.
- Debt Obligations: Confirm the terms of the revolving line of credit mentioned in the September 2024 Note Purchase Agreement, which is contingent on a future $5M public offering (which has since occurred).
- Internal Controls: Review future filings for confirmation that the material weakness regarding sales tax controls has been fully remediated.